Can microbial profiles influence type II inflammation in chronic rhinosinusitis with nasal polyps?

Area of Science:

• Otolaryngology
• Microbiology
• Immunology

Background:

• Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory condition.
• The role of nasal microbiota in CRSwNP pathogenesis and treatment response is increasingly recognized.

Purpose of the Study:

• To compare the effects of dupilumab and functional endoscopic sinus surgery (FESS) on nasal microbiota, type 2 inflammation, and clinical outcomes in CRSwNP patients.
• To investigate the association between specific bacterial compositions and treatment responses.

Main Methods:

• A prospective observational study involving 44 CRSwNP patients treated with either dupilumab or FESS for 6 months.
• Nasal microbiota analysis using culture techniques at baseline and 6 months.
• Measurement of inflammatory biomarkers (IgE, eosinophils) and clinical endpoints (polyp score, SNOT-22, smell test).

Main Results:

• Prevalence of Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa was assessed at baseline.
• Dupilumab and FESS led to significant increases in S. aureus and S. epidermidis, and a decrease in P. aeruginosa.
• Reduced polyp scores, improved SNOT-22 scores, and enhanced smell were observed across bacterial groups, with P. aeruginosa showing smaller improvements. IgE levels decreased with S. aureus and S. epidermidis but increased with P. aeruginosa.

Conclusions:

• Both dupilumab and FESS promote favorable shifts in nasal microbiota by reducing pathogenic bacteria.
• Nasal microbiota composition appears linked to inflammatory and clinical responses to CRSwNP treatments.
• Personalized, microbiome-directed therapies may optimize CRSwNP management by considering individual patient microbiomes.